NOVELIX PHARMACEUTICALS LIMITE — Quarterly Results & Earnings

₹55.78

-3.48%

Profit Growth YoY307.69%Latest quarter

Sales Growth YoY818.18%Latest quarter

Sales CAGR 5Y82.92%5 year compound

Profit CAGR 5Y-2.33%5 year compound

📋

Quarterly Performance

YoY Profit Growth+307.69%

🔥 Exceptional growth

YoY Sales Growth+818.18%

🔥 Exceptional growth

OPM 5Y Average

Operating profit margin

-12.77%

EPS Growth 5Y

-6.26%

Interest Coverage

Higher = safer debt servicing

N/A

ROE

0.64%

ROCE

0.96%

💡

Growth Analysis

NOVELIX PHARMACEUTICALS LIMITE reported YoY profit growth of 307.69% and revenue growth of 818.18% in the latest quarter. Double-digit profit growth above 20% is exceptional — indicates strong business momentum. Over 5 years, sales compounded at 82.92% and profits at -2.33% annually. This is above-average growth for Indian listed companies. Consistent growth over 4-8 quarters is more meaningful than any single quarter. Educational data only.

More on NOVELIX PHARMACEUTICALS LIMITE

Overview Financials PE History Shareholding Quarterly Balance Sheet P&L Cash Flow Healthcare Research, Analytics & Technology Stocks Screener

Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.